Table of Contents
- Trial overview
- Who was studied
- What was tested
- Outcomes measured
- Trial phase and status
- What the results may mean for patients
Trial overview
The PROMISE study, titled PROgnostic value of precision medicine in patients with Myocardial Infarction and non-obStructive coronary artEries, was an interventional trial in patients with MINOCA.[1] It was a Phase 3 study and included 145 participants.[1] The trial was completed.[1]
The study looked at a precision-medicine approach, meaning the team tried to find the specific cause of MINOCA and then use treatment based on that cause.[1] Lysine Aspirin was one of several drugs listed in the study interventions.[1]
Who was studied
The target population was patients with myocardial infarction with non-obstructive coronary arteries (MINOCA).[1] This means people had a heart attack, but the main coronary arteries were not blocked in the usual way.[1]
The source data do not give more details about age limits, sex limits, or other entry rules.[1] Based on the trial data, the key point is that patients had MINOCA and were being studied after this heart event.[1]
What was tested
This trial tested a precision-medicine strategy, which means care was guided by the likely cause of the condition rather than using the same plan for every patient.[1] The study brief says the goal was to see whether careful investigation of the cause of MINOCA and cause-based treatment could improve outcomes.[1]
Lysine Aspirin appeared in the intervention list together with other medicines and procedures, including warfarin, clopidogrel, acetylsalicylic acid, atorvastatin, diltiazem, bisoprolol, acetylcholine chloride, glyceryl trinitrate, and ramipril.[1] The trial data do not say that Lysine Aspirin was the only treatment being tested, so it should be understood as part of the broader study plan.[1]
Outcomes measured
The main outcome was angina status and quality of life at 1-year follow-up.[1] Angina means chest pain or chest discomfort, and quality of life means how well a person feels and functions in daily life.[1]
The outcome was measured with the Seattle Angina Questionnaire (SAQ).[1] This is a patient questionnaire that helps show how chest symptoms affect daily activities and well-being.[1]
Trial phase and status
The study was listed as a Phase 3 trial.[1] Phase 3 studies are later-stage trials that look at how well a treatment strategy works in a larger group of patients.[1]
The trial status was Completed.[1] That means the planned study activities were finished according to the source data.[1]
What the results may mean for patients
For patients with MINOCA, this trial was designed to see whether finding the cause of the heart attack and matching treatment to that cause could improve symptoms and daily life.[1] The main focus was not just on medical tests, but on how patients felt after treatment, especially chest pain and quality of life.[1]
Because the trial data provided here only include the study design and outcomes, they do not show the final results in detail.[1] The available information is most useful for understanding the trial’s goal, target group, phase, and the outcomes it planned to measure.[1]
